Cite
MLA Citation
Sandy Elbitar et al.. “Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015).” Expert opinion on therapeutic patents, vol. 26, n.d., pp. 1377–1392. http://access.bl.uk/ark:/81055/vdc_100039134318.0x000012